Issue 16

Identifying Trends Behind the Top Selling Pharma Drugs

Why not sign up for our future email newsletters? Sign up here.

Included in this issue:

LEAD STORY

Analyzing the 1st Half Drug Sales from Top Pharma Companies

Whilst we’re just past the halfway mark of 2024, mid-year analysis of the top selling drugs for the top 10 pharma companies provides some interesting insights into the demands of the market so far this year. Analysis from PharmaVoice shows that the leading drugs have generated over $55bn in revenue so far - just over 20% of the combined total revenue generated ($243.3bn) by the companies featured.

Read more here.

FEATURED STORIES

Eli Lilly Sees GLP-1 Success, Highlights Ongoing Challenges

Read more here.

Samsung Biologics Becomes First Korean CDMO to Join U.S. Nonprofit Group

Read more here.

Halda Raises $126M to Advance Novel Solid Tumor Therapies

Read more here.

FDA Approves First Nasal Spray for Allergic Reactions

Read more here.

Merck Acquires B-Cell Depletion Therapy from Curon Biopharmaceutical

Read more here.

23andMe Shuts Down Drug Discovery Group, Shifts to Personalized GLP-1 Weight Loss

Read more here.

Ajinomoto to Lay Off 71 Employees as it Streamlines CDMO Business

Read more here.

Rentschler Expands Production Capacity Amid Growing CDMO Demand 

Read more here.

Nanoform Collaborate on Takeda's Plasma-Derived Therapy Development

Read more here.